PDCD1 and neoplasm: made the significant observation that the combination of TMAO with immune checkpoint blockade (anti-PD1 and/or anti-Tim3) led to a substantial reduction in tumor burden and improved survival in a mouse model of PDAC, surpassing the outcomes achieved with TMAO or ICB therapy alone (269).